[A CRISPR/Cas approach to β-haemoglobinopathies].

Area of Science:

• Genetics
• Hematology
• Molecular Biology

Background:

• Beta-haemoglobinopathies are debilitating genetic anemias stemming from impaired adult hemoglobin synthesis.
• Current treatments focus on boosting fetal hemoglobin (HbF) expression to compensate for defective adult hemoglobin.
• CRISPR/Cas9 gene editing offers a novel approach to genetically correct these conditions.

Purpose of the Study:

• To evaluate the efficacy of CRISPR/Cas9 gene editing in reactivating fetal hemoglobin expression.
• To assess the clinical outcomes in patients with severe beta-haemoglobinopathies treated with Casgevy® therapy.
• To identify areas for future therapeutic development, including safety, genotoxicity, and cost-effectiveness.

Main Methods:

• Ex vivo genetic modification of patient hematopoietic stem/progenitor cells using CRISPR/Cas9.
• In vivo assessment of fetal hemoglobin reactivation and editing efficiency in erythroid progeny.
• Clinical evaluation of patient phenotypes and hemoglobin levels post-treatment.

Main Results:

• Over 70 patients with severe beta-thalassemia and sickle cell disease treated with Casgevy®.
• High gene editing efficiency observed in hematopoietic cells.
• Significant clinical phenotype improvement, with normalized or near-normalized hemoglobin levels in most patients.

Conclusions:

• CRISPR/Cas9 gene editing is a powerful therapeutic strategy for beta-haemoglobinopathies, demonstrating significant clinical benefits.
• The Casgevy® therapy shows high editing efficiency and positive clinical outcomes, offering hope for patients.
• Further research is essential to confirm long-term safety, minimize genotoxicity, and reduce therapy costs.